Pegozafermin |
BIO89-100; TEV-47948 |
Phase 3 Clinical |
Teva Pharmaceutical Industries Ltd |
Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|
Efruxifermin |
AKR-001; AMG-876; EFX; Fc-FGF21(RGE) |
Phase 3 Clinical |
Amgen Inc |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus |
Details
|
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) |
AP-025 |
Phase 2 Clinical |
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd |
Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|
BOS-580 |
|
Phase 2 Clinical |
Novartis Pharma Ag |
Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|
HEC-88473 |
HEC-88473; HEC88473 |
Phase 2 Clinical |
Dongguan Hec Taigen Biopharmaceuticals Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity |
Details
|
YH-25724 |
YH-25724; YH25724 |
Phase 1 Clinical |
Yuhan Corp |
Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|
AP-026 |
AP-026; TQA-2226; TQA2226; AP026 |
Phase 1 Clinical |
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight |
Details
|